Cyclerion Therapeutics (CYCN) Competitors $2.94 -0.07 (-2.17%) Closing price 06/25/2025 03:57 PM EasternExtended Trading$2.98 +0.04 (+1.53%) As of 06/25/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. CLNN, KPTI, ATHE, IPA, AKTX, ACRV, BDRX, ELYM, BRNS, and MDCXShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Clene (CLNN), Karyopharm Therapeutics (KPTI), Alterity Therapeutics (ATHE), ImmunoPrecise Antibodies (IPA), Akari Therapeutics (AKTX), Acrivon Therapeutics (ACRV), Biodexa Pharmaceuticals (BDRX), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Clene Karyopharm Therapeutics Alterity Therapeutics ImmunoPrecise Antibodies Akari Therapeutics Acrivon Therapeutics Biodexa Pharmaceuticals Eliem Therapeutics Barinthus Biotherapeutics Medicus Pharma Clene (NASDAQ:CLNN) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Is CLNN or CYCN more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to Clene's net margin of -8,306.00%. Cyclerion Therapeutics' return on equity of -34.02% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Clene-8,306.00% -1,106.30% -105.11% Cyclerion Therapeutics N/A -34.02%-30.68% Does the media favor CLNN or CYCN? In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score. Company Overall Sentiment Clene Neutral Cyclerion Therapeutics Neutral Which has better earnings and valuation, CLNN or CYCN? Cyclerion Therapeutics has higher revenue and earnings than Clene. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$340K108.29-$39.40M-$4.04-1.01Cyclerion Therapeutics$2M4.71-$3.06M-$1.16-2.53 Do analysts rate CLNN or CYCN? Clene currently has a consensus target price of $40.00, suggesting a potential upside of 875.61%. Given Clene's stronger consensus rating and higher probable upside, equities analysts plainly believe Clene is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in CLNN or CYCN? 23.3% of Clene shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 35.3% of Clene shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, CLNN or CYCN? Clene has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. SummaryCyclerion Therapeutics beats Clene on 8 of the 15 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.62M$2.85B$5.42B$8.73BDividend YieldN/A2.69%5.37%4.21%P/E Ratio-2.5320.9825.0319.35Price / Sales4.71301.46404.73112.10Price / CashN/A43.0735.9456.46Price / Book0.907.337.985.50Net Income-$3.06M-$55.19M$3.14B$248.18M7 Day Performance-6.83%1.09%0.86%0.75%1 Month Performance-6.94%8.30%5.13%4.44%1 Year Performance31.03%0.64%38.78%16.85% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics0.7824 of 5 stars$2.94-2.2%N/A+27.6%$9.62M$2M-2.5330Gap DownCLNNClene2.553 of 5 stars$4.42+7.8%$40.00+805.0%-43.1%$39.71M$350K-0.84100KPTIKaryopharm Therapeutics3.7647 of 5 stars$4.54+3.4%$43.20+851.5%-72.5%$39.23M$142.13M-4.45380ATHEAlterity Therapeutics1.4871 of 5 stars$4.41+0.2%$12.00+172.1%+113.9%$39.10MN/A0.0010IPAImmunoPrecise Antibodies1.7206 of 5 stars$0.85+21.2%$4.00+370.6%-7.0%$38.90M$24.00M-1.0980News CoverageGap DownAKTXAkari Therapeutics0.9507 of 5 stars$1.09-8.4%N/A-59.6%$38.29MN/A0.009News CoverageACRVAcrivon Therapeutics3.2349 of 5 stars$1.22+1.7%$17.71+1,352.0%-78.1%$38.25MN/A-0.4558News CoverageBDRXBiodexa Pharmaceuticals0.0566 of 5 stars$1.04-2.8%N/AN/A$38.01M$83K0.0020News CoverageGap UpELYMEliem TherapeuticsN/A$1.26-1.6%N/A-82.0%$37.49MN/A-2.389BRNSBarinthus Biotherapeutics2.3582 of 5 stars$0.91+0.7%$6.25+586.8%-34.5%$36.71M$14.97M-0.61107Gap UpMDCXMedicus Pharma1.7542 of 5 stars$2.66+2.3%$23.50+783.5%N/A$36.10MN/A0.00N/AUpcoming EarningsAnalyst ForecastGap Up Related Companies and Tools Related Companies CLNN Competitors KPTI Competitors ATHE Competitors IPA Competitors AKTX Competitors ACRV Competitors BDRX Competitors ELYM Competitors BRNS Competitors MDCX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto America27 of crypto's most successful minds are about to pull back the curtain… Bitcoin has crushed its all-time h...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
